Henlius has built an integrated and efficient global R&D platform to ensure the highly productive and cost-efficient R&D processes. The global innovation centre is responsible for research and early development from cell line construction and screening to upstream/downstream process development, formulation development and analytical process development with continuous exploration in cutting-edge production technologies. It has established a new payload-linker and conjugate technology platform with proprietary IP rights and a bispecific antibody engineering platform including synthetic humanised llama VHH library (2x1012), VHH- and scFv-based bispecific screening and engineering and linker design.
